London Daily

Focus on the big picture.
Saturday, Jul 12, 2025

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill
Pfizer has made nearly $26bn (£21bn) in revenues in the first three months of the year, the bulk from its Covid-19 vaccine and new pill to treat the virus, prompting fresh accusations of pandemic profiteering.

Covid vaccines have saved many lives around the world and relieved the pressure on health systems, but Pfizer has faced criticism over its vaccine pricing and its refusal to waive patent protection to enable others to make the jab.

Last week 35 campaigners from Global Justice Now, Act-Up London, Just Treatment and Stop Aids protested against what they call pandemic profiteering, and delivered wheelbarrows full of fake money to Pfizer’s UK headquarters in Surrey on the day of the company’s annual shareholder meeting.

The New York-based firm posted total sales of $25.7bn in the first quarter, up 77% from a year earlier. Of this, $13.2bn came from the Comirnaty jab it developed with Germany’s BioNTech, driven by global uptake including jabs for children over the age of five, and booster doses. Pfizer and BioNTech are also seeking US approval for the vaccine’s use in children from six months to four years old.

A further $1.5bn came from Paxlovid, a Covid pill for people who are at high risk of severe disease, including hospitalisation or death. The treatment received emergency approval from the US regulator in late December and has been cleared by the UK and EU.

Pfizer has made tens of billions of dollars during the pandemic from its Covid-related products, as has the Boston-based biotech firm Moderna, which was loss-making until it started selling a Covid-19 vaccine.

Tim Bierley, a pharma campaigner at Global Justice Now, said: “Throughout the pandemic, Pfizer has refused to share its technology and knowhow. Instead, it has maintained monopoly control over its vaccine and treatment, keeping a chokehold on global supply.

“Despite calls from campaigners to allow countries in the global south to manufacture their own vaccines and treatments, Pfizer continues to put profit over people’s health. Pfizer’s revenues almost doubled last year and now it looks like the company’s coffers are set to swell even further. At a time when millions still don’t have access to vaccines or treatments for Covid-19, this continued pandemic profiteering is harrowing.”

Pfizer’s revenues last year doubled to $81.3bn, and it expects to make record sales of $98bn to $102bn this year, half of which will come from Covid products – $32bn from Comirnaty and $22bn from Paxlovid.

On the issue of sharing intellectual property, Pfizer said others would struggle to produce its mRNA vaccine – one of only two on the market – arguing that “it is not as simple as sharing the ‘recipe’”. Manufacture of its vaccine involves more than 280 materials from 86 suppliers in 19 countries.

Other companies, led by AstraZeneca, Britain’s biggest drugmaker, and Johnson & Johnson, a big US firm, went down the not-for-profit route and priced their Covid vaccines at cost during the pandemic. Towards the end of last year, AstraZeneca moved away from its not-for-profit pricing in new contracts, but insists that it is still offering “equitable pricing”.

Pfizer said it also offered tiered pricing, with the wealthier nations paying in the range of about the cost of a takeaway meal, while the upper-middle-income countries were offered doses at roughly half that price and the low- and lower-middle-income countries were offered doses at a not-for-profit price.

In March, the company struck an agreement with Unicef to supply up to 4m treatment courses of Paxlovid to 95 low- and middle-income countries at a not-for-profit price.

Moderna has promised not to enforce its coronavirus vaccine patents in some low- and middle-income countries.
Newsletter

Related Articles

0:00
0:00
Close
A 92-year-old woman, who felt she doesn't belong in a nursing home, escaped the death-camp by climbing a gate nearly 8 ft tall
French Journalist Acquitted in Controversial Case Involving Brigitte Macron
Elon Musk’s xAI Targets $200 Billion Valuation in New Fundraising Round
Kraft Heinz Considers Splitting Off Grocery Division Amid Strategic Review
Trump Proposes Supplying Arms to Ukraine Through NATO Allies
EU Proposes New Tax on Large Companies to Boost Budget
Trump Imposes 35% Tariffs on Canadian Imports Amid Trade Tensions
Junior Doctors in the UK Prepare for Five-Day Strike Over Pay Disputes
US Opens First Rare Earth Mine in Over 70 Years in Wyoming
Kurdistan Workers Party Takes Symbolic Step Towards Peace in Northern Iraq
Bitcoin Reaches New Milestone of $116,000
Biden’s Doctor Pleads the Fifth to Avoid Self-Incrimination on President’s Medical Fitness
Grok Chatbot Faces International Backlash for Antisemitic Content
Severe Heatwave Claims 2,300 Lives Across Europe
NVIDIA Achieves Historic Milestone as First Company Valued at $4 Trillion
Declining Beer Consumption Signals Cultural Shift in Germany
Linda Yaccarino Steps Down as CEO of X After Two Years
US Imposes New Tariffs on Brazilian Exports Amid Political Tensions
Azerbaijan and Armenia are on the brink of a historic peace deal.
Emails Leaked: How Passenger Luggage Became a Side Income for Airport Workers
Polish MEP: “Dear Leftists - China is laughing at you, Russia is laughing, India is laughing”
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Weinstein Victim’s Lawyer Says MeToo Movement Still Strong
U.S. Enacts Sweeping Tax and Spending Legislation Amid Trade Policy Shifts
Football Mourns as Diogo Jota and Brother André Silva Laid to Rest in Portugal
Labour Expected to Withdraw Support for Special Needs Funding Model
Leaked Audio Reveals Tory Aide Defending DEI Record
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
London Stock Exchange Faces Historic Low in Initial Public Offerings
A new online platform has emerged in the United Kingdom, specifically targeting Muslim men seeking virgin brides
Trump Celebrates Independence Day with B-2 Flyover and Signs Controversial Legislation
Boris Johnson Urges Conservatives to Ignore Farage
SNP Ordered to Update Single-Sex Space Guidance Within Days
Starmer Set to Reject Calls for Wealth Taxes
Stolen Century-Old Rolls-Royce Recovered After Hotel Theft
Macron Presses Starmer to Recognise Palestinian State
Labour Delayed Palestine Action Ban Over Riot Concerns
Swinney’s Tax Comments ‘Offensive to Scots’, Say Tories
High Street Retailers to Enforce Bans on Serial Shoplifters
Music Banned by Henry VIII to Be Performed After 500 Years
Steve Coogan Says Working Class Is Being ‘Ethnically Cleansed’
Home Office Admits Uncertainty Over Visa Overstayer Numbers
JD Vance Questions Mandelson Over Reform Party’s Rising Popularity
Macron to Receive Windsor Carriage Ride in Royal Gesture
Labour Accused of ‘Hammering’ Scots During First Year in Power
BBC Head of Music Stood Down Amid Bob Vylan Controversy
Corbyn Eyes Hard-Left Challenge to Starmer’s Leadership
London Tube Trains Suspended After Major Fire Erupts Nearby
Richard Kemp: I Felt Safer in Israel Under Attack Than in the UK
Cyclist Says Police Cited Human Rights Act for Riding No-Handed
×